EcoDrugPlus

Lysyl Oxidase-Like 2a

Ensembl ID : ENSOMYG00000007205
Gene Symbol: LOXL2A
1 Cross references
204 Possible Orthologues:

Lysyl Oxidase-Like 2a

Ensembl ID : ENSOMYG00000006339
Gene Symbol: LOXL2A
1 Cross references
204 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSOMYG00000017705
Gene Symbol: LOXL2B
1 Cross references
206 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSOMYG00000041020
Gene Symbol: LOXL2B
1 Cross references
206 Possible Orthologues:

Macrophage Stimulating 1 Receptor

Ensembl ID : ENSOMYG00000021410
Gene Symbol: MST1R
1 Cross references
187 Possible Orthologues:

Macrophage Stimulating 1 Receptor B

Ensembl ID : ENSOMYG00000022319
Gene Symbol: MST1RB
1 Cross references
187 Possible Orthologues:

Matrix Metallopeptidase 14a (Membrane-Inserted)

Ensembl ID : ENSOMYG00000035480
Gene Symbol: MMP14A
1 Cross references
192 Possible Orthologues:

Matrix Metallopeptidase 14a (Membrane-Inserted)

Ensembl ID : ENSOMYG00000012980
Gene Symbol: MMP14A
1 Cross references
192 Possible Orthologues:

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSOMYG00000042457
Gene Symbol: MMP14B
2 Cross references
190 Possible Orthologues:

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSOMYG00000024040
Gene Symbol: MMP14B
1 Cross references
190 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSOMYG00000020411
Gene Symbol: MMP2
1 Cross references
198 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSOMYG00000043784
Gene Symbol: MMP2
1 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).